Novalung GmbH continues expansion into Scandinavia
Novalung GmbH, the German manufacturer of the world’s leading therapeutic system for extrapulmonary lung support, has signed exclusive agreements with Vingmed Svenska AB and Vingmed AS for distribution of the iLA Membrane Ventilator® in Sweden and Norway, respectively.
Dr. Torsten Rinne, Medical Director of Novalung GmbH, noted: “We have seen the application of the iLA Membrane Ventilator extend increasingly to the support of patients with acute exacerbations of chronic lung disease (COPD). Thus, it is exciting to see how Vingmed has embraced the concept of helping these patients by combining extrapulmonary CO2 removal with non-invasive ventilation as a way of limiting the negative effects that mechanical ventilation can have on their already damaged lungs.”
Of 185 patients added to the company’s iLA Patient Registry in 2009, almost 60% were patients with an acute worsening of a chronic disease (so called exacerbations). The Registry currently includes roughly 10% of the nearly 5,000 patients treated worldwide with the iLA Membrane Ventilator to date. Rinne comments: “Now that we have expanded the iLA Patient Registry to enable all of our customers to actively submit their clinical data, we look forward to a further significant increase in the data pool of COPD patients successfully treated with the iLA Membrane Ventilator. We hope that Vingmed’s customers will be significant contributors to the Registry.”
The Vingmed Group companies were chosen by Novalung due to their decades of experience with innovative medical procedures and their reputation for excellence in customer support. “The iLA Membrane Ventilator is a perfect addition to our current range of products” said Petter Solum of Vingmed AS.
The therapeutic aspects of using the iLA Membrane Ventilator and its relation to other extracorporeal therapies such as ECMO were presented to the participants of the annual meeting of the society of Swedish perfusionists (Swesect) in January 2010 in Visingsö, Sweden.
Novalung GmbH - Driver of a paradigm shift
Novalung’s mission is to develop, produce and market innovative solutions for lung failure, including the world’s first pumpless artificial lung assist device designed to breathe outside the patient’s body. Founded in 2003, the German company operates on a highly international level focusing on the objective to replace damaging invasive mechanical ventilation.
Head of Marketing
Tel.: +49 7133 90 11 130
Fax: +49 7133 90 11 230
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Novalung GmbH continues expansion into Scandinavia here
News-ID: 125616 • Views: 1034
More Releases from Novalung GmbH
NovaPort twin, the Newest Double-Lumen Cannula, Approved
Novalung adds the unique double-lumen cannula to its expanding portfolio of products for the extrapulmonary treatment of lung failure. Now only a single cannula is required instead of two. Novalung announced today that it has received approval for the new NovaPort twin® double-lumen cannula, which is now available for clinical use. The NovaPort® twin cannula was specifically designed for veno-venous vascular access for the iLA activve® system - the Allrounder for
Novalung receives CE mark for iLA activve®
Novalung receives CE mark for iLA activve® With the new all-rounder for extrapulmonary lung support Novalung GmbH is the only company worldwide offering the complete portfolio for both pumpless and pump-driven lung support. Novalung announces receiving CE mark approval for their new pump-driven iLA activve® lung support system. It will be launched in Europe with immediate effect. Respiratory support with iLA activve® enables a treatment environment with awake, mobile patients instead
Novalung and Medos start cooperation
Due to the acquisition of Medos Medizintechnik AG by the private equity fund Zukunftsfonds Heilbronn (“Future Fund of Heilbronn”) the company will cooperate closely in the future with Novalung GmbH, which is expected to strengthen both medical device companies. The Zukunftsfonds Heilbronn (zfhn) announced that it has acquired Medos Medizintechnik AG from Ventizz Capital Partners Advisory AG. The purchase agreement was signed on January 7, 2011. With this
Josef Bogenschuetz joins Novalung as Managing Director
Novalung GmbH prepares for further growth with former Maquet CEO. As of January 1, 2011, Josef Bogenschütz and Dr. Georg Matheis are joint Managing Directors of Novalung GmbH. Bogenschütz will be specifically responsible for Research & Development, Manufacturing, Quality Management and Finance. This addition underscores the company’s focus on the ongoing and efficient expansion of its portfolio of innovative products designed to replace invasive mechanical ventilation. Nicholas L. Strout remains responsible
More Releases for Membrane
Membrane Bioreactor Market 2017-2023 | Key Players GE Water and Process Technolo …
The membrane bioreactor is the technology for wastewater treatment industries, which is witnessing greater adoption in the global market. The market includes the study of various types of configurations, products, applications and geographic analysis. The membrane bioreactor technology is more advanced than conventionally activated sludge method of wastewater management. The technology is efficient due to lower operational and maintenance cost. The market is driven due to increased utilization of the
Membrane Microfiltration Market 2018 - 2028 | By Membrane Type ( PES Membrane F …
Membrane Microfiltration Market: Value and Forecast The global membrane microfiltration market is expected to expand at a CAGR of 7.8% in revenue terms over the forecast period 2018–2028. The global membrane microfiltration market is expected to be dominated by Western Europe with a 22.3% revenue share in 2018. Membrane Microfiltration Market: Product Outlook In water treatment systems, microfiltration membranes help in removing small particles and solids such as iron (rust), manganese (rust), clay, silt and
Membrane Technology Market | Market Growth Analysis 2019
Transparency Market Research (TMR) has recently published a market study on the global membrane technology market, projecting the market to exhibit a CAGR of 9.10% during the period from 2014 to 2019 and reach a market value of US$10.8 bn by the end of the forecast period.The report, titled “Membrane Technology Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2019”, states that the worldwide membrane
Breathable Membrane Market : Industry Analysis 2024
Breathable membranes are semi-porous films or sheets, which allow the exchange of water vapor while preventing liquid water from permeating through. These membranes prevent water from seeping into the roof structure, while providing cold and warm ventilation. Breathable membranes are primarily used in the building & construction industry; they are used as underlay for various types of roofs such as slated pitched roofs and tiled roofs. Large amount of water
United States Photosensory Membrane Market Report 2017
Summary This report studies sales (consumption) of Photosensory Membrane in United States market, focuses on the top players, with sales, price, revenue and market share for each player, covering Company 1 Company 2 Company 3 Company 4 Company 5 Company 6 Company 7 Market Segment by States, covering California Texas New York Florida Illinois Split by product types, with sales, revenue, price, market share and growth rate of each type, can be divided into Type I Type II Split by applications, this report focuses on sales, market share
Global Membrane Switches Sales Market Report 2017
This report studies sales (consumption) of Membrane Switches in Global market, especially in United States, China, Europe and Japan, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering Molex(US) XYMOX(US) Douglas Corporation(US) Fujikura(JP) Human E&C(KOR) Human E&C(KOR)